



ten23 health announces the name change of swissfillon to ten23 health

Visp, January 9th, 2023: ten23 health®, a global contract development and manufacturing organization (CDMO) announced today the change in branding of its in Visp, Switzerland based filling operation from swissfillon to ten23 health.

This represents a natural progression since the acquisition of swissfillon by ten23 health in October 2021 and is intended to unify the company's operations under a single brand and to ease client communication and further strengthen the company's growing global market position.

This change also follows the completion of alignment of the company's internal structure between the two sites Basel and Visp.

The announcement follows the recent confirmation that ten23 health's investment into two large-scale filling lines is on track. The initial phase of construction is complete. The expansion will add new sterile manufacturing lines using the latest isolator technology to ensure optimal sterility assurance levels for high value products.

"We are committed to building ten23 health into a leading global brand, synonymous with Swiss quality and services, focused on Patients, People and Planet," explains Hanns-Christian Mahler, CEO ten23 health.

"Since the acquisition, the teams at Visp and Basel have been working tirelessly to establish a unique customer offering, integrating the pharmaceutical development and testing expertise in Basel with the sterile manufacturing excellence in Visp. With our sterile manufacturing expansions in Visp, we are now gearing up as one team to meet the increasing market demand by providing customized expert solutions for our customers and their patients globally."

About ten23 health

ten23 health®, located in Basel, Switzerland, is the human-centric and sustainable strategic partner of choice for the pharmaceutical industry and biotech start-ups: We develop, manufacture, and test modern medicines. We support our clients in developing differentiated, stable, usable, and safe injectable treatment options for patients. Swissfillon, located in Visp, Switzerland, is a world leader in the sterile production of complex pharmaceutical dosage forms and a wholly-owned subsidiary of ten23 health.

ten23 health combines the latest scientific findings with proven and tested world-class industry and regulatory expertise to forge new paths for supporting clients. We provide our innovative services in a fair and sustainable manner, respecting people's health and the future of our planet. ten23 health is solidly financed through the long-term commitment of 3i Group, an internationally reputable equity partner.

About the company's name

The numeric value for the number of molecules in a sample of one mol is called the Avogadro constant and equals $6.022 \cdot 10^{23}$. The world is built from small units, and not a homogeneous mass.

Media contacts:

ten23 health: Mara Willa, mara.willa@ten23.health; +41 27 948 90 90

3i Group: Kathryn van der Kroft, Kathryn.VanDerKroft@3i.com; +44 20 7975 3021